You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 29, 2025

CLINICAL TRIALS PROFILE FOR PYROTINIB

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for pyrotinib

Subscribe to access the full database, or Get Started Free
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01937689 ↗	Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer	Completed	Chinese Academy of Medical Sciences	Phase 1	Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib in patients with HER2 positive advanced breast cancer: - To evaluate the safety and tolerability of pyrotinib, and the maximum tolerated dose (MTD) - To determine the dose-limiting toxicity (DLT) - To determine the pharmacokinetic profile of Pyrotinib and its metabolites - To assess preliminary antitumor activity - To determine preliminary regimen dose for phase II study - To explore the relationship between biomarkers and the toxicity/efficacy of Pyrotinib.
NCT01937689 ↗	Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer	Completed	Jiangsu HengRui Medicine Co., Ltd.	Phase 1	Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib in patients with HER2 positive advanced breast cancer: - To evaluate the safety and tolerability of pyrotinib, and the maximum tolerated dose (MTD) - To determine the dose-limiting toxicity (DLT) - To determine the pharmacokinetic profile of Pyrotinib and its metabolites - To assess preliminary antitumor activity - To determine preliminary regimen dose for phase II study - To explore the relationship between biomarkers and the toxicity/efficacy of Pyrotinib.
NCT02361112 ↗	Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer	Completed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 1	Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib in combination with capecitabine in patients with HER2 positive metastatic breast cancer: To evaluate the safety and tolerability of pyrotinib, and the maximum tolerated dose (MTD) To determine the dose-limiting toxicity (DLT) To determine the pharmacokinetic profile of Pyrotinib To assess preliminary antitumor activity To determine preliminary regimen dose for phase II study
NCT02361112 ↗	Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer	Completed	Jiangsu HengRui Medicine Co., Ltd.	Phase 1	Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib in combination with capecitabine in patients with HER2 positive metastatic breast cancer: To evaluate the safety and tolerability of pyrotinib, and the maximum tolerated dose (MTD) To determine the dose-limiting toxicity (DLT) To determine the pharmacokinetic profile of Pyrotinib To assess preliminary antitumor activity To determine preliminary regimen dose for phase II study
NCT02378389 ↗	Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer	Unknown status	Jiangsu HengRui Medicine Co., Ltd.	Phase 1	Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib or Pyrotinib in combination with Docetaxel in patients with HER2 positive advanced gastric cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for pyrotinib

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Breast Cancer	50
HER2-positive Breast Cancer	26
Metastatic Breast Cancer	20
Non-small Cell Lung Cancer	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Breast Neoplasms	112
Carcinoma, Non-Small-Cell Lung	13
Brain Neoplasms	8
Lung Neoplasms	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for pyrotinib

Trials by Country

Map
Table

Trials by Country
Location	Trials
China	166
United States	16
Russian Federation	2
Australia	2
Taiwan	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Texas	2
Tennessee	2
New York	2
Florida	2
California	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for pyrotinib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	2
PHASE2	20
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	69
Not yet recruiting	56
NOT_YET_RECRUITING	17
[disabled in preview]	23
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for pyrotinib

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Jiangsu HengRui Medicine Co., Ltd.	47
Fudan University	20
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	9
[disabled in preview]	16
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Other	182
Industry	57
OTHER_GOV	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.